Skin Irritation Clinical Trial
Official title:
A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Diltiazem Hydrochloride 2% Cream in Healthy Subjects, Using a Cumulative Irritant Patch Test Design
Verified date | July 2013 |
Source | Ventrus Biosciences, Inc |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to determine whether Diltiazem Hydrochloride 2% Cream will cause irritation to skin on the back of healthy volunteers after repeated application over 21-days.
Status | Unknown status |
Enrollment | 30 |
Est. completion date | September 2013 |
Est. primary completion date | July 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Are healthy males or females (to be confirmed by medical history) - Are 18 years of age or older - In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomies are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes - If a female of childbearing potential, have a negative urine pregnancy test (UPT) at Screening, and are willing to submit to a pregnancy test at end of study (EOS) - Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events - Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema - Complete a Medical Screening form as well as a Medical Personal History form - Read, understand, and provide signed informed consent Exclusion Criteria: - Have sick sinus syndrome except in the presence of a functioning ventricular pacemaker (confirmed via medical history - Have second-or third-degree AV block except in the presence of a functioning ventricular pacemaker (confirmed via medical history) - Have hypotension (less than 90 mm Hg systolic, determined by performing vital signs) - Have acute myocardial infarction and pulmonary congestion documented by x-ray (confirmed via medical history) - Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction - Are not willing to refrain from using systemic/topical analgesics such as aspirin (81 mg daily aspirin will be allowed), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to Day 1 and during the study (occasional use of acetaminophen will be permitted) - Are using systemic/topical corticosteroids for 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to Day 1 and during the study - Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications - Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study - Have psoriasis and/or active atopic dermatitis/eczema - Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child - Have a known sensitivity to constituents present in the material being evaluated - Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site - Have received treatment for any type of internal cancer within 5 years prior to study entry - Have a history of, or are currently being treated for skin cancer - Are currently participating in any clinical testing - Have any known sensitivity to adhesives - Have received any investigational treatment(s) within 4 weeks prior to study entry |
Country | Name | City | State |
---|---|---|---|
United States | TKL Research | Paramus | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Ventrus Biosciences, Inc |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean cumulative irritation score of Diltiazem Hydrochloride 2% Cream in healthy skin of humans. | The primary variable of interest is the mean cumulative irritation score. The mean cumulative irritation score for each subject, product and site will be calculated as the sum of the irritation scores divided by the number of readings. The total cumulative irritation score for each subject and product will also be calculated as the sum of irritation scores on each of 21 evaluation days. A normalized total score for each patch will be calculated by summing the total irritation scores for all subjects, dividing by the number of readings and multiplying by 210. These parameters will be tested pairwise for product differences using Fisher's protected least significant differences in the context of the analysis of variance (ANOVA), including effects of subject and product (ie, randomized complete blocks). All pairwise differences will be tested. No adjustment for multiple comparisons will be made. | 21 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01806831 -
Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent ("Biocellulose Mask", "Farhorm®") in Patients Receiving Laser Treatment
|
N/A | |
Completed |
NCT02297841 -
Repeated Insult Patch Test of Personal Lubricants
|
N/A | |
Completed |
NCT02968446 -
Effect of Vitamin D After Application With Valchlor
|
Early Phase 1 | |
Completed |
NCT03397862 -
A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System
|
Phase 1 | |
Completed |
NCT01892657 -
Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test
|
Phase 4 | |
Withdrawn |
NCT02400320 -
Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol
|
Phase 4 | |
Not yet recruiting |
NCT02645110 -
Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations
|
N/A | |
Completed |
NCT01888887 -
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser
|
N/A | |
Completed |
NCT01887808 -
Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30
|
N/A | |
Completed |
NCT01887860 -
Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50
|
N/A | |
Completed |
NCT01892410 -
Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash
|
N/A | |
Completed |
NCT01892423 -
Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion
|
N/A |